A quick simple method of determining platelet aggregability following glycoprotein IIb/IIIa receptor inhibitor administration

Cardiology

Volumn 91, Issue 3, 1999, Pages 156-160

  Poullis, Michael ^a,b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Aprotinin; GP IIb IIIa; Microaggregation; Platelets; Trasylol

Indexed keywords

ABCIXIMAB; ADENOSINE DIPHOSPHATE; ADRENALIN; APROTININ; CITRIC ACID; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN;

ARTICLE; CONTROLLED STUDY; COULTER COUNTER; HUMAN; HUMAN CELL; METHODOLOGY; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE AGGREGATION;

ANTIBODIES, MONOCLONAL; APROTININ; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

EID: 0032877021     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000006903     Document Type: Article

References (10)

1. Garbarz E, Farah B, Vuillemenot A, Andre F, Angioi M, Machecourt J, Bassand JP, Wolf JE, Danchin N, Prendergast B, Iung B, Vanhanian A: 'Rescue' abciximab for complicated percutaneous transluminal coronary angioplasty. Am J Cardiol 1998;82:800-803.
2. Adelman AG, Caramori PRA, Cohen EA, Chisholm R, Cote G, Ducas J, O'Neill BJ, Tcheng JE: The role of glycoprotein IIb/IIIa platelet inhibition in percutaneous coronary intervention in the stent era. Can J Cardiol 1998; 14:1057-1066.
3. vanHout BA, Bowman L, Zelinger DJ, Simoons ML: Costs and effects in therapy for acute coronary syndromes: The case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. Am Heart J 1998;135:S98-S106.
4. Aristides M, Gliksman M, Rajan N, Davey P: Effectiveness and cost effectiveness of single bolus treatment with abciximab (Reo Pro) in preventing restenosis following percutaneous transluminal coronary angioplasty in high risk patients (see comments). Heart 1998;79:12-17.
5. Storey RF, Wilcox RG, Heptinstall S: Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonis potency. Circulation 1998;98: 1616-1621.
6. 2+ on GP IIb-IIIa interactions with integrilin: Enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997;96:1488-1494.
7. Coller BS, Lang D, Scudder LE: Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor. Circulation 1997;95: 860-867.
8. Mascelli MA, Worley S, Veriabo NJ, Lance ET, Jordan RE: Rapid assessment of platelet function with a modified whole blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy. Circulation 1997;96:3860-3866.
9. Heptinstall S, May JA, Glenn JR, Sanderson HM, Dickinson JP, Wilcox RG: Effects of ticlopidine administered to healthy volunteers on platelet function in whole blood. Thromb Haemost 1995;74:1310-1315.
10. Thompson N, Scrutton M, Wallis R: Particle volume changes associated with light transmittance changes in the platelet aggregometer: Dependence upon aggregating agent and effectiveness of stimulus. Thromb Res 1986;41:615-626.